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Abstract
Fluid resuscitation is widely used, and many patients are therefore
exposed to plasma volume expanders. Among these, colloids,
particularly hydroxyethyl starches, have been shown in recent
experiments and clinical studies to induce acute kidney injury. The
mechanisms of colloid-induced acute kidney injury remain in-
completely elucidated. The risks associated with colloid osmotic
pressure elevation in vivo and the high incidence of osmotic
nephrosis lesions in experimental models and clinical studies
indicate that hydroxyethyl starches can no longer be considered
safe.
Plasma volume expansion is often required in the operating
room, emergency department, or intensive care unit. The
safety of plasma volume expanders therefore deserves careful
consideration. Low renal perfusion is a major risk factor for
acute kidney injury (AKI), and plasma volume expansion is
therefore crucial for its prevention. On the contrary, among
plasma volume expanders, colloids can induce kidney injury,
as shown many years ago [1-5]. Recent experiments and
clinical studies have supplied further information on the renal
toxicity of some colloids, particularly hydroxyethyl starches
(HESs) [6-9].
Colloid-induced AKI with morphological abnormalities of the
proximal tubular cells, or osmotic nephrosis, has been
reported after the infusion of low-molecular-weight dextran or,
more recently, HES. The tubular lesions reflect the accu-
mulation of proximal tubular lysosomes due to pinocytosis of
exogenous osmotic solutes (for example, mannitol, sucrose,
iodinated contrast media, or colloids) [10]. The tubular cells
swell because they contain numerous lysosomes and endo-
cytotic vacuoles. Furthermore, the oncotic force of colloids
may induce further renal function impairment by decreasing
the renal filtration pressure [3]. The exact mechanisms of
colloid-induced AKI remain incompletely elucidated, and
controversy exists regarding the relative roles for morpho-
logical and functional changes [4].
Because HESs are widely used and AKI is strongly
associated with decreased survival, the risk of AKI associated
with various HESs needs to be determined. Three genera-
tions of HES have been developed over time. Newer HESs
have lower molecular weight and lower degree of substi-
tution, two changes that should decrease accumulation and
toxicity [11]. Third-generation HESs have molecular weights
lower than 200 kDa and degrees of hydroxyl substitution
lower than 0.5, the most common combination being
130/0.4. First-generation and second-generation HESs have
been found to induce AKI in heart surgery patients, in brain-
dead organ donors, and in patients with sepsis [6,7,9,12].
The most recent randomized controlled trial, which included a
large number of patients, showed a higher incidence of AKI
with 10% HES 200/0.5 than with Ringer lactate solution in
intensive care unit patients with sepsis [6]. Both the
administration of large volumes and high in vitro colloid
osmotic pressure (COP) may contribute to renal toxicity. No
large randomized controlled trial establishing the safety of
third-generation HESs is available.
In the previous issue of Critical Care, Hüter and coworkers
report an interesting experiment aimed at improving our
understanding of HES-induced AKI [1]. Using hemodilution in
a model of isolated kidney perfusion, they assessed the renal
effects of one second-generation HES solution and one third-
generation HES solution comparative to a crystalloid.
Although their model was very different from the clinical
situation, and the number of studied animals was limited,
morphological studies of the kidneys yielded useful infor-
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mation. After in vivo hemodilution, creatinine clearance was
higher with the crystalloid than with either HES. As expected,
the glomerular filtration pressure was much higher with the
crystalloid. For a similar mean arterial pressure, the COP was
considerably lower after crystalloid infusion and was similarly
increased with both HESs. Although the two HESs had
different in vitro COP values, their in vivo COP effect was
similar. The rapid in vivo degradation of HES 130/0.4 usually
results in a high plasma COP, as illustrated here. After
isolated kidney perfusion, the plasma COP remained similar
in the two HES groups, but creatinine clearance was lower
with the second-generation 10% HES 200/0.5. This result
suggests an additional role for a delayed decrease in
glomerular filtration, independent of filtration pressure.
Morphological examination showed that the lesions of
osmotic nephrosis were more severe in the two HES groups,
despite the limited volumes infused. Tubular lesions appeared
as early as 6 hours after exposure and were associated with
greater severity of the interstitial inflammation and tubular
dysfunction in the 10% HES 200/0.5 group.
The results of this experiment have implications for clinical
practice. First, the in vivo COP of the fluid used may have an
early effect on the glomerular filtration pressure, as recently
suggested in patients resuscitated for shock [8]. With
polydispersed macromolecules such as HES, the in vivo
COP differs from the in vitro COP. Also, third-generation
HESs can induce osmotic nephrosis similar to that seen with
older compounds, within a few hours of exposure. Recent
systematic reviews have alerted clinicians to the renal toxicity
of HES [13,14]. In the absence of large randomized con-
trolled trials, doubts about the safety of third-generation HES
persist, and the results reported by Hüter and colleagues
leave room for concern about the safety of widespread use of
third-generation HES. Furthermore, HESs have been
reported to induce not only AKI, but also irreversible chronic
renal failure [10,15,16].
The question therefore is should HESs or other colloids ever
be used for fluid resuscitation? There is no evidence from
randomized controlled trials that colloids improve patient
outcomes [17]. Thousands of patients included in
randomized controlled trials have been safely resuscitated
using only crystalloids [17]. Furthermore, the study by Hüter
and coworkers shows that colloid toxicity and the risk of
colloid-induced AKI can be assessed experimentally before
colloids are considered for use in humans.
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